Hoechst & Rhone-Poulenc Merge To Create Aventis

1 December 1998

After weeks of speculation, Hoechst AG and Rhone-Poulenc have announcedthat they are to merge their life sciences businesses into a new company called Aventis. The new entity will initially comprise the pharmaceutical and agricultural activities of both groups and represents the first phase of a two-step plan which will eventually lead to a full merger of the two European giants. This is expected to occur within the next two to three years, once they divest their non-life sciences assets.

Aventis will have its global headquarters in Strasbourg, France, and will have a combined turnover of approximately $20 billion. The companies say that with a combined R&D budget of nearly $3 billion, Aventis "will have one of the most competitive innovation capabilities in the industry," and one of the leading sales and marketing forces in the world.

Combining the life sciences assets of R-P and Hoechst is expected to provide "additional operational efficiency" with synergies of more than $1.2 billion over the next three years, with 60% of the estimated savings coming from pharmaceuticals, including personnel cuts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight